Damora Therapeutics Rebrands, Reports Strong $535M Cash, and Outlines Accelerated Pipeline Development

summarizeSummary

Galecto, Inc. has officially rebranded as Damora Therapeutics, Inc. (DMRA) following an acquisition, reporting a strong cash position of $535 million and outlining accelerated development timelines for its blood disorder pipeline.

check_boxKey Events

• Official Rebranding and Ticker Change

  The company officially changed its name from Galecto, Inc. to Damora Therapeutics, Inc. and its Nasdaq trading symbol to 'DMRA', effective March 10, 2026. This follows the completion of a previously announced acquisition of privately held Damora.

• Strong Cash Position Reported

  The company reported approximately $535 million in cash and cash equivalents as of February 28, 2026, providing an anticipated financial runway into Phase 3 development of its lead program.

• Significant Capital Infusion Confirmed

  The strong cash position is a result of a concurrent private investment of approximately $285 million in November 2025 and gross proceeds of approximately $316 million from a recently closed public offering in February 2026.

• Pipeline Advancement Milestones Set

  Damora Therapeutics plans to submit an IND or CTA for DMR-001 in mid-2026, for DMR-002 in the second half of 2026, and for DMR-003 in 2027. Two clinical proof-of-concept datasets for DMR-001 are expected beginning mid-2027.

auto_awesomeAnalysis

This filing marks a significant strategic pivot for the company, officially rebranding from Galecto, Inc. to Damora Therapeutics, Inc. with a new ticker symbol 'DMRA'. The name change follows the completion of a previously announced acquisition and is accompanied by a robust financial update, reporting approximately $535 million in cash and cash equivalents as of February 28, 2026. This strong cash position, bolstered by a recent $316 million public offering and a $285 million private investment, provides an anticipated runway into Phase 3 development for its lead program, DMR-001. The company also outlined clear milestones for its mutant calreticulin-targeted therapeutics pipeline, including multiple IND/CTA submissions in 2026 and 2027, and clinical proof-of-concept data expected mid-2027. This comprehensive update signals a well-funded and strategically focused company with a clear path for advancing its therapeutic programs.